Pfizer Commercial Oncology is introducing the world to the next era of cancer care. With a growing portfolio of novel therapies, industry-leading R&D, and a goal of delivering eight breakthroughs by 2030 across major cancer types, we're translating cutting-edge science into market-shaping impact. Here, you'll partner with exceptional colleagues across scientific, medical, and manufacturing teams, backed by advanced digital and AI-enabled infrastructure and the authority to accelerate medicines from discovery to delivery. Guided by our values of courage, excellence, equity, and joy, you'll have the opportunity to stretch your skills and build a career that evolves with you—across teams, roles, and the Pfizer enterprise. Join us in making history. The Lung cancer portfolio is one of the fastest growing portfolios in Pfizer Oncology and includes the following in-line brands: LORBRENA and BRAFTOVI/MEKTOVI Lung. Lung cancer is the most common cancer, and LORBRENA, our ALK+ inhibitor has been prescribed to over 12,000 patients since launching in the US in 2018. At ASCO 2026, the unprecedented 7-year follow analysis of the pivotal Phase 3 CROWN trial was presented and published. This practice-changing data is expected to solidify LORBRENA’s position in treating patients with ALK+ metastatic non-small cell lung cancer (NSCLC).
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Senior